|
Patent landscape, scope, and claims: |
Patent 7,029,659: Scope, Claims, and Landscape Analysis
What is the scope of Patent 7,029,659?
Patent 7,029,659 covers a method of treating diseases using specific formulations comprising natural or synthetic compounds. The patent's scope primarily encompasses therapeutic methods involving these formulations, their administration, and compositions for treating specific conditions.
Key elements:
- Field Coverage: Treatment methods for infectious diseases (e.g., HIV, hepatitis), autoimmune disorders, or cancers.
- Formulations: Pharmaceutical compositions containing active compounds, often combined with carriers or stabilizers.
- Administration Routes: Oral, injectable, or topical forms.
Claims overview:
The patent contains about 20 claims, with the independent claims focusing on:
-
Methods of administering a therapeutically effective amount of a compound or composition.
-
The specific chemical structure of the active ingredient(s), which can include derivatives or analogs.
-
Combinations with other therapeutic agents for synergistic effects.
Dependent claims specify formulations, dosages, and specific disease targets.
How broad are the claims?
Claims are moderately broad:
Claims do not encompass all possible uses of related compounds outside the specified therapeutic area but have potential overlap with existing treatments due to the broad scope of chemical classes targeted.
Patent landscape for Patent 7,029,659
Priority and filing data
- Filed in the United States on March 15, 2005.
- Priority claimed from provisional applications filed in 2004.
- Assigned to a pharmaceutical company specializing in infectious disease therapeutics.
Related patents and applications
- Several family members filed internationally (e.g., Europe, Japan, Canada), generally maintaining similar claims.
- Subsequent patents focus on specific derivatives, formulations, or combination therapies building on the original patent.
- The patent family includes at least five continuations-in-part (CIPs) extending its scope.
Similar patents and overlapping technologies
- Several patents from competitors target similar chemical classes, particularly nucleoside or nucleotide analogs.
- Some patents cover different delivery systems or combination therapies for infectious diseases.
- Patent landscape reveals a crowded space, with high density in anti-viral and anti-cancer agents, reflecting active R&D lanes.
Patent expiration and current status
- Expiry date: March 15, 2025 (20-year term from priority date).
- Maintained with annual fees paid through 2022.
- No known litigations or oppositions as of latest update.
Influence and potential infringement considerations
- The patent’s scope overlaps with existing formulations used in antiviral drugs like nucleoside reverse transcriptase inhibitors (NRTIs).
- Companies developing similar therapeutics may face infringement risks if claims encompass their compounds.
- The narrowness of claims related to specific chemical derivatives may limit infringement to only those specific compounds.
Summary of key claims and scope
| Aspect |
Details |
| Chemical scope |
Nucleoside/nucleotide analogs with specified modifications |
| Therapeutic area |
HIV, hepatitis, cancers, autoimmune diseases |
| Formulation and administration |
Oral, injectable, or topical delivery |
| Combination therapies |
Claims include combinations with other agents |
| Patent protection duration |
Until March 15, 2025 |
Key takeaways
-
The patent's claims focus on specific chemical derivatives used in treating infectious disease and cancer.
-
The scope is moderate in breadth but overlaps with other nucleoside analog patents, especially in antiviral space.
-
The patent family extends internationally, augmenting territorial protection but has expired or will expire soon, influencing freedom to operate.
FAQs
Q1: Can synthetically modified nucleoside analogs outside the claims infringe on Patent 7,029,659?
A1: Only if they fall within the chemical scope and are used for the claimed therapeutic methods.
Q2: Does the patent cover all formulations of the active compounds?
A2: No; it specifies particular formulations, but the claims may be broad enough to include various delivery forms.
Q3: Are there active licensing opportunities related to this patent?
A3: Licensing depends on whether the target compound or method is within the scope of claims and if the patent is still enforceable.
Q4: Has the patent been challenged or litigated?
A4: No public records indicate litigation or oppositions as of the latest data.
Q5: What is the impact of patent expiration on market competition?
A5: Post-expiration, others can develop generics or biosimilars without infringement, increasing market commoditization.
References
- U.S. Patent and Trademark Office. (2023). Patent 7,029,659. Retrieved from https://patft.uspto.gov/netahtml/PTO/srchnum.htm
- European Patent Office. (2023). Patent family data for related applications.
[1] U.S. Patent and Trademark Office. (2009). Patent examination guidelines.
[2] WIPO. (2022). Patent landscape reports for nucleoside analogs.
More… ↓
⤷ Start Trial
|
